NeXeption, Not The Rule: Another Twist On Asset-Based Financing
This article was originally published in Start Up
As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?
You may also be interested in...
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.
In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.